论文部分内容阅读
严重的生长激素(GH)耐受、胰岛素样生长因子(IGF)-1和其主要的结合蛋白(IGFBP)-3的低水平与肝硬化蛋白分解状态有关。为了评估GH耐受的可逆性和由此对蛋白充分利用和安全性的影响,本研究对20例GH治疗的肝硬化患者进行了随机、双盲、安慰剂对照的研究。 方法:对20例经组织学证实的肝硬化患者,在7天内随机双盲地每天皮下注射重组人生长激素,剂量为0.25IU/kg或等体积的安慰剂。患者用病房标准饮食,但允许摄入其要求的补充饮食,尽管患者因腹水而限制盐,但蛋白质摄入无限制。每日上午8时取空腹血测定血清GH、IGF-1、IGFBP-3、胰岛素、葡萄糖和肝功
Severe growth hormone (GH) tolerance, low levels of insulin-like growth factor (IGF) -1 and its major binding protein (IGFBP) -3, are associated with cirrhosis of the liver. To assess the reversibility of GH tolerance and the consequent impact on protein utilization and safety, we conducted a randomized, double-blind, placebo-controlled study of 20 GH-treated patients with cirrhosis. METHODS: Twenty patients with histologically confirmed cirrhosis were randomized to double blind daily injections of recombinant human growth hormone at a dose of 0.25 IU / kg or an equal volume of placebo within 7 days. Patients are given a standard diet with a ward, but are allowed to take their supplemental diet as required. There is no restriction on protein intake, although the patient limits the salt due to ascites. Fasting blood samples were taken at 8 AM every day for serum GH, IGF-1, IGFBP-3, insulin, glucose and liver function